Cafe Coffee Day IPO Indigo IPO GVK Airports IPO

IPO issue season is going to starting in coming days. Cafe coffee day, Indigo and GVK airport Developers are offering their public issue in near by days.

Cafe Coffee day IPO:

Cafe Coffee Day (CCD) is doing largest chain coffee shop business in India. People will called its as Coffee Day. Now this coffee day is comming to IPO for Rs.1,150 crore. Coffee day was submitted Public issue application at SEBI. Coffee day was quoted in DRHP (Draft Red Herring Prospectus) as their aim for Rs1,150 crore in initial public issue.  

Coffee Day  wants list in BSE (Bombay Stock Exchange) and NSE (National Stock Exchange). Coffee Day was reserved Rs.15 crore worth shares for it employs.   

Cafe Coffee Day (CCD) promoter VG Siddartha have 54.78% share in coffee day. Now he is the Chairmen and Managing Director CMD for Coffee Day. Total promoters have 92.74% share in coffee day. International Private Equity companies KKR, Stan chart, New Silk route companies are invested in Coffee day. KKR company have 3.43% share in coffee day. Nandan nilekani one of the promoter of infosys and chief of Adhar Card project have 1.77% share in coffee day. 

       

Cafe Coffee Day first retail coffee shop was established in 1996 at Banglore. Now its have 1500 stores across the India.  

Coffee Day captured 46% market share in coffee shop business. Other 4 companies are giving competition in tis coffee shop sector. Coffee day have 4 times extra network than than other  4 companies network. 

2013-14 total gross profit is Rs. 1,154 Crore and Operating profit is Rs.189 Crores.  

Indigo IPO:

Indigo National Airways Company also coming to IPO. Indigo also submitted DRHP at SEBI. Indigo offering for Rs.2500 crore public issue. 

Inter Globe Enterprises offering airways services with Indigo brand. This company was promoted by Rahul Batia Traveling sector industrialist and Rakesh Gangwal Ex. chief executive US Airways. 

Indigo placed in top position in National Airways Business services. Not only that Indigo is running with profits now.  

GVK AIRPORTS DEVELOPER:

GVK group dividing airports wing from GVK Power and Infrastructure. GVK offering public issue in GVK airports developers Ltd for Rs.3,000 crore funds. 
GVK Power and Infrastructure announced loss Rs.834.68 crores in 2014-15 year. 
GVK airports developers Ltd is developing now International Airports at Mumbai and Bangalore. 

Flipkart IPO Public Issue

Indian Online store Flipkart has taken investments from investors. 2.5 billion dollars were taken from 15 different investment organisations. Now Flipcart thinking about accumulate funds through loans.   

Flipkart taken 700 million dollars investments in last December 2014. At that time company valuation calculated as 11.5 billion dollars. 


Within four months company valuation reaches 15 billion dollars (near about 1 Lach Crore Rupees). So company directors don't want to decrease their share. 

So they are going to loans.  Now company wants to 600-800 million dollars as investments, and the discussions was started. 

As per news it is going to accumulate 200 million dollars in first year. But Flipcart not revealed this news. 

One more news is spreading about flipkart public issue (IPO) will open within 18 months. 

Mylan rejected TEVA offer

Mylan pharma rejected TEVA pharma offer on the base of cash -and-stock buying offer. TEVA given buyout offer @ rate of $82 per share. But MYLAN rejected offer. In this scenario mylan share price traded at $72.50 on monday with the loss of $3.76

NATCO MYLAN TEVA and COPAXONE

Teva Generic medical industry from Israel. Recently this company passed a resolution in their board of directors meeting, to purchase US based another generic medical industry, that is Mylan. 

These companies are top two companies of world in generic medical field.

Teva wanted to close this deal  $82 for share. Offer value is Rs.2,50,000 Cr ($,000 Cr Dollars) 

As per Teva chairmen Peter burg Teva board of directors passed a resolution unanimously. 

But Mylan not responded.

It’s a Big Deal :

If Teva purchase mylan, it’s an a big deal in pharma industry. This two companies yearly earning is $ 3,000 Cr in Rs.1,80,000 Cr. If Teva deal completes with Mylan, Teva Reach first place world wide in generic medicine industry.  At right now US based mylan is in second place in world wide.

Ranbaxy reached world's 5^th place after Sun pharma merge with Ranbaxy. TEVA and Mylan facing big competitions from developing companies like Ranbaxy. Teva feels that if the deal complete with Mylan, then  facing competitions are easy.  Mylan started their activity in India in 2012 under the supervision of Rajiv malik president and Executive director of Mylan. Rajiv Malik is Indian descent.

About TEVA :

Established     : 1901

Place                 : Peta Tikwa, Israil

Net profit          : $ 2,030 Cr

Shares Listed : New york Stock Exchange, Tel Aviv Stock Exchange

Working Are   : Israil, South America, North America, Iropa

Placed at world’s first place under generic Medicine Companies

About Mylan :

Established     : 1961

Place                 : Pensilinia, USA

Net Profit          : $ 770 Cr

Shares Listed : Nasdac

Working Are    : North America, Iropa, Asia Pacipic, Africa and middle east

Placed at world’s Second place under generic Medicine Companies

  NATCO crushing :

If this deal completes NATCO pharma may face some patent problems on ‘COPAXONE MEDICINE. 

With this issue only Natco pharma stock price was gone up to  6% below in 22^nd April 2015 trading. At end of the session natco phrma stock price closed with 4% loss at Rs. 2,064/-

‘COPAXONE’ medicene have full demand world wide which is using in nerve related diseases treatment.  In 2014 COPAXONE sales value is Rs.26,460 Cr.  TEVA get 50% profit with copaxone sales in total TEVA’s profit. 

With this figures we can understand what is the role of COPAXONE in TEVA Pharma. COPAXONE patent rights are ending 2015 September, Which patent rights have TEVA.

Natco along with Mylan got a world wide permission for generic version of COPAXONE.  TEVA reached some courts. Some courts given judgement in the favor of NATCO. But one case is still pending in USA courts. NATCO got a permission for this product sales in USA through USFDA.

If TEVA completes the deal with mylan. Here one question is raising what will happened in the deal of NATCO and MYLAN on the marketing of COPAXONE.  

FED.NONI

 

About company

Company

BSY Marketing India Private Limited is a benchmark company of USA Federation Trading Co. Ltd. of Hong Kong, B-Swan Holding Ltd. New York State, USA, and its subsidiary the USA Federation Trading company Ltd., with unique and state-of-the-art contemporary technology from Hawaii, USA, to manufacture BSY 100% Noni Leaven with USA FDA accreditation and other downstream derivatives of acclaimed Morinda Citrifolia - Noni.

It focuses its operations from its sprawling modern facilities located within the mainland China across Hong Kong. Internationally the parent company is offering encapsulated support to its subsidiaries with its integrated expertise in management and with world class products. Besides, it is incorporating world class R & D, Production, Sales, Modern Warehousing, Logistics and Other services in Singapore, East/West Malaysia, Philippines, Indonesia, Thailand and Brunei. Few other countries are on the pipeline.